눈에 묻으면 몇 분간 물로 조심해서 씻으시오. 가능하면 콘택트렌즈를 제거하시오. 계속 씻으시오.
P321
(…) 처치를 하시오.
P330
입을 씻어내시오.
P332+P313
피부 자극이 생기면 의학적인 조치· 조언을 구하시오.
P337+P313
눈에 대한 자극이 지속되면 의학적인 조치· 조언를 구하시오.
P403+P233
용기는 환기가 잘 되는 곳에 단단히 밀폐하여 저장하시오.
P405
밀봉하여 저장하시오.
P501
...에 내용물 / 용기를 폐기 하시오.
NFPA 704
0
2
0
ABT450 C화학적 특성, 용도, 생산
개요
Paritaprevir hydrate, a second-generation NS3/4A protease
inhibitor, is a component of the all-oral, interferon-free hepatitis
C virus combination therapy developed by Enanta Pharmaceuticals
and AbbVie. The fixed-dose tablet of paritaprevir, ombitasvir
(XXV, NS4A replication complex inhibitor), and ritonavir (cytochrome
P450 inhibitor) taken in combination with dasabuvir (X,
NS5B polymerase inhibitor) was approved for the treatment of
chronic HCV genotype 1 in the USA and EU in 2014, and further approved for treatment of genotype 4 chronic HCV infection
without cirrhosis by the US FDA in 2015. After 12 weeks
of combination treatment, high sustained virological response
rates have been demonstrated in clinical trials.205 Paritaprevir joins
other marketed NS3/4A inhibitors, including telaprevir, boceprevir,
simeprevir, and vaniprevir (XXXVIII), which inhibit a critical enzymatic
complex for HCV replication. It exhibits potent antiviral
activity against HCV genotype 1a and 1b strains, with EC50
values of 1.0 and 0.21 nM respectively. As paritaprevir is metabolized
by CYP3A4, ritonavir, a CYP3A inhibitor with no direct HCV
antiviral properties, is dosed concurrently to boost paritaprevir
exposure, raising the mean plasma half-life to ca. 5.5 h and allowing
for once-daily dosing. While several development routes for
paritaprevir have been published in the patent literature, no process
route has been disclosed to date. Perceptibly the most scalable
route is described below; no yields for this route have been
reported. Notably, the synthesis of a closely related compound
that shares the same macrocylic core has been reported
by AbbVie on kilogram scale.
용도
Paritaprevir is a pharmaceutical drug that is used in the treatment of hepatitis C virus in patients with HCV genotype 1 infection. It inhibits an important viral phosphoprotein, NS5A, which is involved in viral replication, assembly, and secretion.
정의
ChEBI: An azamacrocycle which is used which is in combination with dasabuvir sodium hydrate, ombitasvir and ritonavir (under the trade name Viekira Pak) for treatment of chronic hepatitis C virus genotype 1 infection as well as cirrhosis of the liver.
